Reciprocal repression between P53 and TCTP

Nature Medicine

Volumn 18, Issue 1, 2012, Pages 91-99

  Amson, Robert ^a   Pece, Salvatore ^b,c,d   Lespagnol, Alexandra ^a   Vyas, Rajesh ^e   Mazzarol, Giovanni ^b,c,d   Tosoni, Daniela ^b,c,d   Colaluca, Ivan ^b,c,d   Viale, Giuseppe ^b,c,d   Rodrigues Ferreira, Sylvie ^a   Wynendaele, Jessika ^e   Chaloin, Olivier ^f   Hoebeke, Johan ^f   Marine, Jean Christophe ^e   Di Fiore, Pier Paolo ^b,c,d   Telerman, Adam ^a  

^a CNRS   (France)

^b FIRC INSTITUTE OF MOLECULAR ONCOLOGY   (Italy)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITY OF LEUVEN   (Belgium)

^f INSTITUT DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN MDM2; PROTEIN P53; SERTRALINE; THIORIDAZINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER GRADING; CORRELATION ANALYSIS; DRUG ACTIVITY; FEEDBACK SYSTEM; GENE; GENE ACTIVITY; GENE FUNCTION; GENETIC SCREENING; HAPLOINSUFFICIENCY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; STEM CELL; TCTP GENE; UBIQUITINATION;

ANIMALS; APOPTOSIS; BREAST NEOPLASMS; FEEDBACK, PHYSIOLOGICAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HAPLOINSUFFICIENCY; HCT116 CELLS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; NEOPLASTIC STEM CELLS; NERVE TISSUE PROTEINS; PROGNOSIS; PROMOTER REGIONS, GENETIC; PROTEOLYSIS; PROTO-ONCOGENE PROTEINS C-MDM2; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITINATION;

MUS; MUS MUSCULUS;

EID: 84855535930     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2546     Document Type: Article

References (60)

1. Vogelstein, B. & Kinzler, K.W. Cancer genes and the pathways they control. Nat. Med. 10, 789-799 (2004). (Pubitemid 39070849)
2. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
3. Telerman, A. et al. A model for tumor suppression using H-1 parvovirus. Proc. Natl. Acad. Sci. USA 90, 8702-8706 (1993). (Pubitemid 23277738)
4. Weaver, V.M. et al. Reversion of the malignant phenotype of human breast cells in three-dimensional culture and in vivo by integrin blocking antibodies. J. Cell Biol. 137, 231-245 (1997). (Pubitemid 27167310)
5. Hendrix, M.J. et al. Reprogramming metastatic tumour cells with embryonic microenvironments. Nat. Rev. Cancer 7, 246-255 (2007). (Pubitemid 46480969)
6. Telerman, A. & Amson, R. The molecular programme of tumour reversion: the steps beyond malignant transformation. Nat. Rev. Cancer 9, 206-216 (2009).
7. Amson, R.B. et al. Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the Drosophila seven in absentia gene. Proc. Natl. Acad. Sci. USA 93, 3953-3957 (1996). (Pubitemid 26144229)
8. Linares-Cruz, G. et al. p21WAF-1 reorganizes the nucleus in tumor suppression. Proc. Natl. Acad. Sci. USA 95, 1131-1135 (1998).
9. Nemani, M. et al. Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. Proc. Natl. Acad. Sci. USA 93, 9039-9042 (1996). (Pubitemid 26282014)
10. Roperch, J.P. et al. Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. Nat. Med. 4, 835-838 (1998).
11. Tuynder, M. et al. Biological models and genes of tumor reversion: cellular reprogramming through tpt1/TCTP and SIAH-1. Proc. Natl. Acad. Sci. USA 99, 14976-14981 (2002). (Pubitemid 35334595)
12. Tuynder, M. et al. Translationally controlled tumor protein is a target of tumor reversion. Proc. Natl. Acad. Sci. USA 101, 15364-15369 (2004). (Pubitemid 39441547)
13. Li, F., Zhang, D. & Fujise, K. Characterization of fortilin, a novel antiapoptotic protein. J. Biol. Chem. 276, 47542-47549 (2001).
14. Chen, S.H. et al. A knockout mouse approach reveals that TCTP functions as an essential factor for cell proliferation and survival in a tissue-or cell type-specific manner. Mol. Biol. Cell 18, 2525-2532 (2007).
15. Susini, L. et al. TCTP protects from apoptotic cell death by antagonizing bax function. Cell Death Differ. 15, 1211-1220 (2008). (Pubitemid 351984751)
16. Liu, H., Peng, H.W., Cheng, Y.S., Yuan, H.S. & Yang-Yen, H.F. Stabilization and enhancement of the antiapoptotic activity of mcl-1 by TCTP. Mol. Cell. Biol. 25, 3117-3126 (2005). (Pubitemid 40464314)
17. Hsu, Y.C., Chern, J.J., Cai, Y., Liu, M. & Choi, K.W. Drosophila TCTP is essential for growth and proliferation through regulation of dRheb GTPase. Nature 445, 785-788 (2007). (Pubitemid 46279709)
18. Bazile, F. et al. Complex relationship between TCTP, microtubules and actin microfilaments regulates cell shape in normal and cancer cells. Carcinogenesis 30, 555-565 (2009).
19. Brioudes, F., Thierry, A.M., Chambrier, P., Mollereau, B. & Bendahmane, M. Translationally controlled tumor protein is a conserved mitotic growth integrator in animals and plants. Proc. Natl. Acad. Sci. USA 107, 16384-16389 (2010).
20. Amson, R., Kubiak, J.Z., Van Montagu, M. & Telerman, A. Could TCTP contribute to Armin Braun's paradigm of tumor reversion in plants? Cell Cycle 10, 1 (2011).
21. Koziol, M.J., Garrett, N. & Gurdon, J.B. Tpt1 activates transcription of oct4 and nanog in transplanted somatic nuclei. Curr. Biol. 17, 801-807 (2007). (Pubitemid 46635117)
22. MacDonald, S.M., Rafnar, T., Langdon, J. & Lichtenstein, L.M. Molecular identification of an IgE-dependent histamine-releasing factor. Science 269, 688-690 (1995).
23. Sanchez, J.C. et al. Translationally controlled tumor protein: a protein identified in several nontumoral cells including erythrocytes. Electrophoresis 18, 150-155 (1997).
24. Bommer, U.A. & Thiele, B.J. The translationally controlled tumour protein (TCTP). Int. J. Biochem. Cell Biol. 36, 379-385 (2004).
25. Bommer, U.A. et al. Roles of the translationally controlled tumour protein (TCTP) and the double-stranded RNA-dependent protein kinase, PKR, in cellular stress responses. Oncogene 29, 763-773 (2010).
26. Vassilev, L.T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004). (Pubitemid 38174664)
27. el-Deiry, W.S. et al. WAF1, a potential mediator of p53 tumor suppression. Cell 75, 817-825 (1993). (Pubitemid 23346378)
28. Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K. & Elledge, S.J. The p21 Cdkinteracting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816 (1993). (Pubitemid 23346377)
29. Hoffman, W.H., Biade, S., Zilfou, J.T., Chen, J. & Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 277, 3247-3257 (2002). (Pubitemid 34953189)
30. Johnson, R.A., Ince, T.A. & Scotto, K.W. Transcriptional repression by p53 through direct binding to a novel DNA element. J. Biol. Chem. 276, 27716-27720 (2001).
31. Godar, S. et al. Growth-inhibitory and tumor-suppressive functions of p53 depend on its repression of CD44 expression. Cell 134, 62-73 (2008). (Pubitemid 351905743)
32. Lin, T. et al. p53 induces differentiation of mouse embryonic stem cells by suppressing Nanog expression. Nat. Cell Biol. 7, 165-171 (2005). (Pubitemid 40268131)
33. Rho, S.B. et al. Anti-apoptotic protein TCTP controls the stability of the tumor suppressor p53. FEBS Lett. 585, 29-35 (2011).
34. Haupt, Y., Maya, R., Kazaz, A. & Oren, M. Mdm2 promotes the rapid degradation of p53. Nature 387, 296-299 (1997). (Pubitemid 27220766)
35. Kubbutat, M.H., Jones, S.N. & Vousden, K.H. Regulation of p53 stability by Mdm2. Nature 387, 299-303 (1997). (Pubitemid 27220767)
36. Juven-Gershon, T. et al. The Mdm2 oncoprotein interacts with the cell fate regulator Numb. Mol. Cell. Biol. 18, 3974-3982 (1998). (Pubitemid 28287921)
37. Colaluca, I.N. et al. NUMB controls p53 tumour suppressor activity. Nature 451, 76-80 (2008).
38. Lowe, S.W., Schmitt, E.M., Smith, S.W., Osborne, B.A. & Jacks, T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362, 847-849 (1993). (Pubitemid 23132161)
39. Lees-Miller, S.P., Sakaguchi, K., Ullrich, S.J., Appella, E. & Anderson, C.W. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the aminoterminal transactivation domain of human p53. Mol. Cell. Biol. 12, 5041-5049 (1992).
40. Fiscella, M. et al. Mutation of the serine 15 phosphorylation site of human p53 reduces the ability of p53 to inhibit cell cycle progression. Oncogene 8, 1519-1528 (1993). (Pubitemid 23189048)
41. Tibbetts, R.S. et al. A role for ATR in the DNA damage-induced phosphorylation of p53. Genes Dev. 13, 152-157 (1999). (Pubitemid 29061945)
42. Selvakumaran, M. et al. Immediate early up-regulation of bax expression by p53 but not TGF-1: a paradigm for distinct apoptotic pathways. Oncogene 9, 1791-1798 (1994). (Pubitemid 24163410)
43. Nakano, K. & Vousden, K.H. PUMA, a novel proapoptotic gene, is induced by p53. Mol. Cell 7, 683-694 (2001). (Pubitemid 32706359)
44. Wu, W.S. et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 123, 641-653 (2005).
45. Deng, S.S. et al. Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human. Genomics Proteomics Bioinformatics 4, 165-172 (2006).
46. Pardal, R., Clarke, M.F. & Morrison, S.J. Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3, 895-902 (2003). (Pubitemid 37500174)
47. Pece, S. et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 140, 62-73 (2010).
48. Cicalese, A. et al. The tumor suppressor p53 regulates polarity of self-renewing divisions in mammary stem cells. Cell 138, 1083-1095 (2009).
49. Menendez, D., Inga, A. & Resnick, M.A. The expanding universe of p53 targets. Nat. Rev. Cancer 9, 724-737 (2009).
50. Pokholok, D.K. et al. Genome-wide map of nucleosome acetylation and methylation in yeast. Cell 122, 517-527 (2005). (Pubitemid 41191151)
51. Bommer, U.A. et al. The mRNA of the translationally controlled tumor protein P23/TCTP is a highly structured RNA, which activates the dsRNA-dependent protein kinase PKR. RNA 8, 478-496 (2002).
52. Qu, L. et al. Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3β. Genes Dev. 18, 261-277 (2004). (Pubitemid 38199252)
53. Baltzis, D. et al. The eIF2 kinases PERK and PKR activate glycogen synthase kinase 3 to promote the proteasomal degradation of p53. J. Biol. Chem. 282, 31675-31687 (2007). (Pubitemid 350044850)
54. Yoon, C.H., Lee, E.S., Lim, D.S. & Bae, Y.S. PKR, a p53 target gene, plays a crucial role in the tumor-suppressor function of p53. Proc. Natl. Acad. Sci. USA 106, 7852-7857 (2009).
55. Passer, B.J. et al. The p53-inducible TSAP6 gene product regulates apoptosis and the cell cycle and interacts with Nix and the Myt1 kinase. Proc. Natl. Acad. Sci. USA 100, 2284-2289 (2003). (Pubitemid 36297491)
56. Amzallag, N. et al. TSAP6 facilitates the secretion of translationally controlled tumor protein/histamine-releasing factor via a nonclassical pathway. J. Biol. Chem. 279, 46104-46112 (2004). (Pubitemid 39491604)
57. Yu, X., Harris, S.L. & Levine, A.J. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 66, 4795-4801 (2006).
58. Lespagnol, A. et al. Exosome secretion, including the DNA damage-induced p53-dependent secretory pathway, is severely compromised in TSAP6/Steap3-null mice. Cell Death Differ. 15, 1723-1733 (2008).
59. Susini, L. et al. Siah-1 binds and regulates the function of Numb. Proc. Natl. Acad. Sci. USA 98, 15067-15072 (2001). (Pubitemid 34013970)
60. Fiucci, G. et al. Siah-1b is a direct transcriptional target of p53: identification of the functional p53 responsive element in the siah-1b promoter. Proc. Natl. Acad. Sci. USA 101, 3510-3515 (2004).